Squarepoint
RNAC icon

Squarepoint’s Cartesian Therapeutics RNAC Stock Holding History

Squarepoint’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.8M Buy
2,238,486
+2,220,273
+12,191% +$15.8M 0.02% 906
2025
Q4 		$131K Buy
+18,213
New +$147K ﹤0.01% 3987
2025
Q1 		– Sell
-10,652
Closed -$191K – 5276
2024
Q4 		$191K Buy
10,652
+259
+2% +$5.24K ﹤0.01% 4488
2024
Q3 		$168K Buy
+10,393
New +$162K ﹤0.01% 3751
2024
Q2 		– Sell
-3,623
Closed -$70.6K – 4553
2024
Q1 		$70.6K Sell
3,623
-2,187
-38% -$46.4K ﹤0.01% 3841
2023
Q4 		$120K Buy
5,810
+4,813
+483% +$144K ﹤0.01% 3723
2023
Q3 		$31.7K Buy
997
+28
+3% +$935 ﹤0.01% 3674
2023
Q2 		$32.5K Sell
969
-2,729
-74% -$97.7K ﹤0.01% 3471
2023
Q1 		$154K Buy
+3,698
New +$174K ﹤0.01% 2881
2022
Q3 		– Sell
-925
Closed -$36K – 3366
2022
Q2 		$36K Buy
+925
New +$27.4K ﹤0.01% 2736
2022
Q1 		– Sell
-505
Closed -$49K – 3412
2021
Q4 		$49K Buy
+505
New +$54.3K ﹤0.01% 3024
2021
Q3 		– Sell
-391
Closed -$49K – 3354
2021
Q2 		$49K Buy
+391
New +$46.6K ﹤0.01% 3107
2021
Q1 		– Sell
-1,341
Closed -$122K – 3538
2020
Q4 		$122K Buy
1,341
+234
+21% +$20.3K ﹤0.01% 2677
2020
Q3 		$82K Buy
+1,107
New +$84.8K ﹤0.01% 2317
2020
Q2 		– Sell
-3,297
Closed -$238K – 2483
2020
Q1 		$238K Buy
+3,297
New +$318K 0.01% 1400

Other funds holding RNAC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return

Squarepoint's RNAC Position: Q1 2026 in Review

Squarepoint increased its Cartesian Therapeutics (RNAC) stake by 12,191% in Q1 2026, buying an estimated $15.8M and bringing the position to 2,238,486 shares worth $13.8M. The position accounts for 0.02% of the portfolio, ranked #906.

Squarepoint first reported a position in RNAC in Q1 2020 and has held it in 15 quarters since. 83 funds tracked by Wall St. Rank hold RNAC as of Q1 2026.

  • Squarepoint held 2,238,486 shares of Cartesian Therapeutics worth $13.8M as of Q1 2026.
  • Squarepoint bought 2,220,273 Cartesian Therapeutics shares in Q1 2026, an estimated $15.8M.
  • Cartesian Therapeutics made up 0.02% of Squarepoint's portfolio in Q1 2026, its #906 holding.
  • Squarepoint first reported a position in Cartesian Therapeutics in Q1 2020 and has held it in 15 quarters since.
  • 83 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.